Frenova describes itself as is the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research.
“F1RST Up is a logical extension of our renal research services,” Kurt Mussina, VP and General Manager of Frenova Renal Research, told us.
The program, which stands for Frenova Rapid STart Up, will provide service offering to clients who require accelerated startup.
The program already has several founding members with backgrounds in in vascular access and care, cardio-renal conditions, chronic kidney disease (CKD), end stage renal disease (ESRD), cardiovascular disease, rare diseases, infectious diseases and transplant.
“F1RST Up is the rapid startup component of Frenova’s site network, a highly select group of exceptionally performing renal research sites with large, diverse patient populations that are available and ready to enroll quickly to help clients get studies underway faster,” said Mussina.
According to Mussina, the model helps facilitate faster and more efficient enrollment by using standardized forms and documents, in addition to pre-negotiated budgets and contracts with those in the network.
The company plans to extend the F1RST Up network overtime.